Filter News

Head And Neck Cancer Therapeutics Market Size Will Attain USD 3.80 BN By 2030

Published: Nov 07, 2022

According to Nova one advisor, the global Head And Neck Cancer Therapeutics market was valued at USD 1.40 billion in 2021 and it is expected to hit around USD 3.80 billion by 2030 with a CAGR of 12.9% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7428

Key Takeaways:

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest growing segment during the forecast period. This can be attributed to high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge who can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7428

Increasing advancements in diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth as they are cost-effective and more specific to target over surgeries. Increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of market. 

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide. 

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for treatment of disease. 

Moreover, increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant, is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA. 

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance aid to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Report Scope of the Head And Neck Cancer Therapeutics Market

Report Coverage

Details

Market Size

USD 3.80 Billion by 2030

Growth Rate

CAGR of 12.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Therapy type, route of administration, distribution channel, and Region,

Companies Mentioned

Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Clinigen Group plc.; Bristol-Myers Squibb Company; AstraZeneca; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd; F. Hoffmann-La Roche Ltd.

 

Therapy Type Insights 

The immunotherapy segment dominated the market and is expected to witness a significant revenue share of 43.9% in 2021. According to the Cancer Research Institute, there are currently 2 approved PD-L1 inhibitors including Nivolumab (Opdivo), and Pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer. Dostarlimab (Jemperli) is currently in Phase II clinical trials for metastatic or recurrent head and neck squamous cell carcinoma. Thus, approval of new immunotherapy drugs is expected to fuel segment growth. 

The targeted therapy is second largest revenue generating segment in 2021. This can be attributed to promising and effective results associated with the use targeted therapy as a treatment option for head and neck cancer patients. This therapy includes EGFR monoclonal antibodies (nimotuzumab, panitumumab, Cetuximab, zalutumumab) and tyrosine kinase inhibitors (erlotinib, Gefitinib, dacomitinib, afatinib, lapatinib). However, the side-effects associated with long term use of these therapies are linked to several complications that may restrain the segment growth.

Route Of Administration Insights 

The injectable segment dominated the market and is expected to witness a significant revenue share of 88.8% in 2021. This can be attributed to factors such as the wide availability of the large number of HNC therapeutic drugs in injectable form, better availability, and high efficiency of injectable drugs. There are a large number of drugs available in injectable form. For instance, Keytruda manufactured by Merck & Co., Inc., is administrated by intravenous route as an infusion in patients with head and neck cancer. 

Oral route of administration is expected to be the fastest growing segment over the forecast period due to increasing oral therapeutics drugs for the treatment of patients with HNC. Inlyta (axitinib) is an orally administered HNC drug that has completed a phase 2 clinical trial in patients with head and neck cancer. Thus, successful completion of the trial and subsequent launch is projected to drive segment growth. 

Distribution Channel Insights 

The retail and specialty pharmacies segment dominated the market and accunted for the largest revenue share of 57.8% in 2021. The dominance can be attributed to the high preference of manufacturers for distributing their products owing to easy access to medicines and low distribution costs. According to Drug Channels Institute’s report 2021, Humana specialty pharmacy, Accredo, CVS Specialty, Walgreens stores, and Optum specialty pharmacy were the world’s top five specialty pharmacies.

Moreover, the retail and specialty pharmacies segment is expected to be fastest growing segment over the forecast period. This can be attributed to easy availability of a wide range of products. In addition, the rising number of retail pharmacies in both developed, as well as developing countries, has led to high growth of this segment. HNC product are widely available in specialty and retail pharmacies. This is expected to drive the growth of the segment. 

Regional Insights 

North America dominated the market and accounted for the largest revenue share of around 44.9% in 2021. Government support for the development of the healthcare sector, favorable reimbursement policies, high awareness about the disease, and easy accessibility to quality medical facilities are among the key factors responsible for regional market growth. 

In Asia Pacific, the market for head and neck cancer therapeutics is anticipated to grow at the fastest rate over the forecast period. The increasing geriatric populations and increasing prescription of immunotherapy drugs such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo) for the treatment of various types of HNC are expected to drive the market growth in coming years. 

Some of the prominent players in the Head And Neck Cancer Therapeutics Market include:

  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • Clinigen Group plc.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • F. Hoffmann-La Roche Ltd. 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Head And Neck Cancer Therapeutics market

  • Therapy Type
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
  • Route of Administration
    • Injectable
    • Oral
  • Channel
    • Retail & Specialty Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7428

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/

 

 

Back to news